Verizon’s Converged Health Management, a remote patient-monitoring medical platform designed to help clinicians and patients manage patients’ health in between doctor visits, just received U.S. Food and Drug Administration (FDA) 510(k) clearance to run on the iOS (Apple, Inc.) mobile operating system.
Patients and clinicians now will be able to access Verizon’s solution on their iPhones and can use their iPads to access the Converged Health Management portal.
In addition, Converged Health Management added Telcare and Genesis blood glucose monitors to its line of biometric devices to its secure, device-agnostic platform. These join the list of other available biometric devices, including Ideal Life’s blood pressure cuff, glucose monitor model, pulse oximeter, and weight scale.
The new enhancements give our customers added choice to deliver and customize mobile health solutions to patients and employees. In fact, 59 percent of physicians who use mobile medical apps do so on a tablet device, and from within that group, most prefer the iPad.*
“There is value in having a range of biometric devices connect to the Converged Health Management platform,” said Julie Kling, director of mobile health, Verizon. “With our new enhancements, Verizon is driving innovation for our clients by helping them to change how healthcare is delivered to patients.”
“Verizon would like to continue to build an ecosystem of devices to create a diverse network of meaningful mobile health experiences that connect clinicians and their patients so they can be cared for in new and more effective ways,” added Kling.
Verizon Converged Health Management is designed for healthcare providers, health insurance and large private employers that are looking for ways to monitor at-home care compliance and engage patients in healthier lifestyle choices, all with the goal of helping clinicians reduce hospital readmissions.
Verizon provides an integrated fabric of health IT solutions that address the biggest challenges facing the U.S. healthcare system today, including the ability to securely and efficiently exchange sensitive patient data across hospital, payer and physician networks via voice, video and data. This includes interconnected cloud, mobility, machine-to-machine and security solution sets.
Verizon’s vision is to create a healthier world in which connected individuals and healthcare organizations are empowered with innovative technologies that improve health outcomes, transform access to care and lower the cost of healthcare.
*"The Year of the Big EHR Switch" Confirms Physicians Favor iPad and Mobile Applications http://www.prweb.com/releases/2013/5/prweb10553455.htm
The CHM Device is a remote monitoring software solution intended to collect and store biometric data from physiological measurement devices intended for use in the home. The CHM Device also allows for the automated transmission of the biometric data to a remote secure server via existing mobile telecommunications and/or Internet infrastructure. The stored biometric data is accessible by clinicians for analysis and intervention. Patients can also review the stored biometric data and receive educational and motivational content from clinicians. The CHM Device can be used as a standalone device or in conjunction with supported patient monitoring devices, such as a glucometer, weight scale, pulse oximeter and blood pressure monitor.
The CHM Device is not intended for use in surgical rooms, intensive care units, intermediate or step-down units or emergency vehicles. It is not interpretive, nor is it intended for diagnosis or as a replacement for the oversight of healthcare professionals. It does not provide real-time or emergency monitoring.
Warnings and Precautions
There is risk that data housed by the CHM Device may become lost or corrupt as a result of a failure of the CHM Device. The risk of loss or corruption of health data in the CHM Device is similar to the risks associated with data storage systems a hospital or clinic might use when storing electronic medical records. Such risks should be understood by users of CHM Device, including clinicians and patients.
